Abstract

For many years, the interleukin-1 receptor family member ST2 was an orphan receptor that was studied in the context of inflammatory and autoimmune disease. However, in 2005, a new cytokine — interleukin-33 (IL-33) — was identified as a functional ligand for ST2. IL-33/ST2 signalling is involved in T-cell mediated immune responses, but more recently, an unanticipated role in cardiovascular disease has been demonstrated. IL-33/ST2 not only represents a promising cardiovascular biomarker but also a novel mechanism of intramyocardial fibroblast–cardiomyocyte communication that may prove to be a therapeutic target for the prevention of heart failure.

Author affiliations

1. GRB-804, Division of Cardiology, Massachusetts General Hospital, 55 Fruit Street, Boston, Massachussetts 02114, USA.
   Email: rkakkar@partners.org
2. Brigham and Women's Hospital, Harvard Medical School, Partners Research Facility, Room 279 65 Landsdowne Street, Cambridge, Massachusetts 02139, USA.
   Email: rlee@partners.org

MORE ARTICLES LIKE THIS

These links to content published by NPG are automatically generated.